Cancer therapy may be too targeted: Genetic landscape of rare cancer acts as guide for future clinical trials — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/03/140316153025.htm
source : http://www.sciencedaily.com/releases/2014/03/140316153025.htm
source : http://www.sciencedaily.com/releases/2014/02/140227134704.htm
source : http://www.sciencedaily.com/releases/2014/02/140218142354.htm
source : http://www.sciencedaily.com/releases/2014/02/140220141611.htm
source : http://www.sciencedaily.com/releases/2014/02/140213184818.htm
source : http://www.sciencedaily.com/releases/2014/02/140212144513.htm
source : http://www.sciencedaily.com/releases/2014/01/140124110720.htm
Such is the case with two proteins identified by scientists at The University of Texas MD Anderson Cancer Center that fit on to the same binding site on an important cellular growth factor receptor called FGFR2 with starkly different results. "There is competition for binding to FGFR2 and one of the two competitors, phospholipase Cγ1 (Plcγ1), will increase cancer cell metastasis. The other protein inhibits the opportunity for this to occur," said John Ladbury, Ph.D., professor of Biochemistry and Molecular Biology. …
“In previous findings published over the past 10 years, our teams have described key mechanisms in these critical proteins,” said Khalid Sossey-Alaoui, PhD, Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic. “A key component in the deadly metastatic potential of TNBC tumors is that they spread through tissues outside the breast very quickly. The two proteins that we studied, WAVE3 and TGF-β, when together, promote tumor aggressiveness.” “We found important biological implications,” said William Schiemann, PhD, an associate professor, Division of General Medical Sciences-Oncology, Case Western Reserve School of Medicine, and co-leader of the Breast Cancer Program at the Case Comprehensive Cancer Center…
NCI scientists found that tumors of germ-free mice (mice completely lacking these microorganisms), or mice treated with antibiotics to deplete the gut of bacteria, were largely impaired in their ability to respond to immunotherapy that slows cancer growth and prolongs survival. The mice were also impaired in their ability to respond to mainstay chemotherapy drugs such as oxaliplatin and cisplatin. These findings in mice may underscore the importance of microorganisms in optimal cancer treatment outcomes in humans. …